| Autor: |
Atsushi Nakajima, Mio Fujimaki, Yuki Arai, Kento Emori |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Journal of neurogastroenterology and motility. 28(3) |
| ISSN: |
2093-0879 |
| Popis: |
Elobixibat, an ileal bile acid transporter (apical sodium-dependent bile acid transporter) inhibitor, was recently launched in Japan for the treatment of chronic idiopathic constipation. We conducted an interim analysis of post-marketing surveillance to evaluate the safety and efficacy of elobixibat in elderly patients with chronic constipation and compared the efficacy according to administration time.Safety and efficacy outcomes were evaluated through patient interviews for 4 weeks.Adverse drug reactions (ADRs) were observed in 5.24% of the 1049 patients analyzed; diarrhea (2.19%) and abdominal pain (1.81%) were the most common. A serious ADR of death was reported in one patient (0.10%). The incidence of ADRs in the ≥ 65-year old or ≥ 75-year-old subpopulation was similar to that in the total patient population. Mean bowel movements per week significantly increased from 2.9 ± 2.5 at baseline to 5.0 ± 3.1 (The results suggested that elobixibat was well-tolerated and efficacious in elderly patients with chronic constipation and can be administered before any meals. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
